Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives “Outperform” Rating from BMO Capital Markets

BMO Capital Markets reissued their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report issued on Wednesday, Benzinga reports. They currently have a $234.00 price objective on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on the stock. The Goldman Sachs Group cut shares of Alnylam Pharmaceuticals from a buy rating to a neutral rating and cut their price target for the company from $230.00 to $173.00 in a research note on Friday, February 16th. Royal Bank of Canada reiterated an outperform rating and issued a $235.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Piper Sandler boosted their price target on Alnylam Pharmaceuticals from $210.00 to $217.00 and gave the stock an overweight rating in a research report on Thursday, December 14th. JPMorgan Chase & Co. raised their price objective on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a neutral rating in a research report on Thursday, February 1st. Finally, Wolfe Research began coverage on Alnylam Pharmaceuticals in a report on Thursday, February 15th. They set a peer perform rating on the stock. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $216.12.

Alnylam Pharmaceuticals Trading Up 1.6 %

ALNY opened at $154.39 on Wednesday. Alnylam Pharmaceuticals has a 1-year low of $143.52 and a 1-year high of $218.88. The stock has a market capitalization of $19.45 billion, a PE ratio of -43.37 and a beta of 0.39. The firm has a 50-day moving average price of $161.00 and a two-hundred day moving average price of $170.62.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. During the same quarter in the prior year, the business earned ($1.68) earnings per share. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, research analysts predict that Alnylam Pharmaceuticals will post -4.61 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Quent Capital LLC raised its position in Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 123 shares during the last quarter. KB Financial Partners LLC bought a new position in Alnylam Pharmaceuticals during the 1st quarter worth approximately $35,000. Anchor Investment Management LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $38,000. Robeco Institutional Asset Management B.V. lifted its position in shares of Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 12,513 shares during the period. Finally, GAMMA Investing LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $52,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.